“…As the routine measurement of these markers in ascetic fluid is not easy in clinical practice and more invasive. These results were similar to a previous report by [8] who demonstrated a positive correlation between a group of tumor markers in serum and ascetic fluid in malignant ascites. On the contrary, [9] found that ascetic CEA was significantly higher than serum CEA in patients with advanced gastric cancer patients with ascites due to carcinomatosis.…”
Background & objectives: Data regarding tumor marker usefulness in diagnosing ascites of unknown etiology and determining its malignant nature are conflicting. We aim to assess the diagnostic value of ascitic and serum tumor markers in ascites of unknown etiology and to evaluate their usefulness besides other laboratory tests in a diagnostic work-up in those patients. Design & setting: A prospective case-control study conducted at Assiut University hospital and oncology institute. Patients & Methods: Three groups were included; Group I: 41 patients with ascites of unknown etiology Group II: 7 Patients with TB ascites and Group III:14 patients with cirrhotic ascites. We assessed the CEA, CEA mRNA, CA15-3, CA19.9, CA125, AFP and PSA in serum and ascetic fluid. A diagnostic work-up for group I included: IPD test, ultrasound, CT, ascetic fluid cytology, SAAG, Laparotomy and biopsy. Results: Ascetic fluid and serum levels of CA15-3 and CA125 were significantly increased in group I and were significantly increased in histopathologically proved malignant ascites compared to TB and cirrhotic ascites. In group I, CA 125 was significantly higher in ascites than serum. With the exception of PSA, all tumor markers significantly correlated in serum and ascetic fluid. No significant difference in the level of ascetic CEA messenger RNA was detected between the 3 groups. Cytology had 53% sensitivity, 94% specificity and CA 125 & CA15-3 had 81% sensitivity and 75% specificity in detection of malignant ascites repectively. Laparotomy and biopsy: diagnosed malignnancy in 53.3% and TB in 13.3%. Conclusions: A diagnostic work-up including SAAG, tumor markers in the serum and ascetic fluid may help in adjunct with ascetic fluid cytology, laparotomy and biopsy, imag- ing and other laboratory tests in diagnosing ascites of unknown etiology
“…As the routine measurement of these markers in ascetic fluid is not easy in clinical practice and more invasive. These results were similar to a previous report by [8] who demonstrated a positive correlation between a group of tumor markers in serum and ascetic fluid in malignant ascites. On the contrary, [9] found that ascetic CEA was significantly higher than serum CEA in patients with advanced gastric cancer patients with ascites due to carcinomatosis.…”
Background & objectives: Data regarding tumor marker usefulness in diagnosing ascites of unknown etiology and determining its malignant nature are conflicting. We aim to assess the diagnostic value of ascitic and serum tumor markers in ascites of unknown etiology and to evaluate their usefulness besides other laboratory tests in a diagnostic work-up in those patients. Design & setting: A prospective case-control study conducted at Assiut University hospital and oncology institute. Patients & Methods: Three groups were included; Group I: 41 patients with ascites of unknown etiology Group II: 7 Patients with TB ascites and Group III:14 patients with cirrhotic ascites. We assessed the CEA, CEA mRNA, CA15-3, CA19.9, CA125, AFP and PSA in serum and ascetic fluid. A diagnostic work-up for group I included: IPD test, ultrasound, CT, ascetic fluid cytology, SAAG, Laparotomy and biopsy. Results: Ascetic fluid and serum levels of CA15-3 and CA125 were significantly increased in group I and were significantly increased in histopathologically proved malignant ascites compared to TB and cirrhotic ascites. In group I, CA 125 was significantly higher in ascites than serum. With the exception of PSA, all tumor markers significantly correlated in serum and ascetic fluid. No significant difference in the level of ascetic CEA messenger RNA was detected between the 3 groups. Cytology had 53% sensitivity, 94% specificity and CA 125 & CA15-3 had 81% sensitivity and 75% specificity in detection of malignant ascites repectively. Laparotomy and biopsy: diagnosed malignnancy in 53.3% and TB in 13.3%. Conclusions: A diagnostic work-up including SAAG, tumor markers in the serum and ascetic fluid may help in adjunct with ascetic fluid cytology, laparotomy and biopsy, imag- ing and other laboratory tests in diagnosing ascites of unknown etiology
“…Tüzün et al (2009) showed just the contrary in a study determining the levels of tumour markers including CA125, CEA and CA19.9 in samples of serum and ascites fluid. In this study, they found the levels of tumour markers correlated in serum and ascites fluid and revealed that the tumour markers were high in patients with a malignancy (Tuzun et al, 2009). In our study patients with ascites were excluded from the study and the study group was different from the study mentioned above in which only patients with a gynaecological pathology were included.…”
“…Another argument which supports this idea is the production of CA 125, CYFRA and CEA by the normal mesothelial cells. Of much utility is also the serum AFP concentration, which was higher than that of the ascitic fluid and which can detect hepatocellular carcinoma with a higher sensitivity than the ascitic cytology (6).…”
CA 125 is one of the most popular tumor markers usually synthetized by normal and malignant cells of different origins. Increased levels can be found in both benign and malignant conditions in fluids with different origins such as pleural effusion, ascites, ovarian cysts fluids, amniotic fluid and even pancreatic cyst fluids. This is a literature review of the largest studies regarding various conditions in which increased levels of CA 125 can be found and their clinical significance.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.